Clinical Trials Logo

Clinical Trial Summary

Use of three intralymphatic injections of peanut allergen one month apart to induce tolerance to peanut in peanut allergic people.


Clinical Trial Description

Eligible subject undergo a baseline blinded oral peanut challenge. Then the peanut ILIT as described above. Pretreatment with antihistamines, leukotriene modifier and albuterol before each treatment. Following the three ILIT peanut injections a repeat blinded oral peanut challenge is performed. Blood is drawn at each of the 5 study visits for a variety of tests trying to elucidate the mechanism(s) of the induction of tolerance to peanut. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04200989
Study type Interventional
Source Scripps Health
Contact
Status Withdrawn
Phase Phase 1/Phase 2
Start date March 1, 2021
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06260956 - Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg N/A
Enrolling by invitation NCT04604431 - Intervention to Reduce Early (Peanut) Allergy in Children N/A
Recruiting NCT06192914 - EPAP, Interviewstudy
Recruiting NCT05695261 - Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients Phase 2
Completed NCT05038904 - Preventing Anaphylaxis With Acalabrutinib Phase 2
Recruiting NCT05407012 - TRANS-FOODS: Preventing Peanut Allergy Through Improved Understanding of the Transcutaneous Sensitisation Route, Novel Food Processing and Skin Care Adaptations N/A